Carotid Wallstent Monorail Endoprosthesis
Boston Scientific Corp · Decision date Sep 19, 2025
What did the FDA approve?
FDA records P050019/S043 as a supplement to PMA P050019, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Sep 19, 2025.
FDA approval order statement
approval for changes to the manufacturing process intended to increase the potential for consistently producing an inner guidewire lumen within the specified height
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 19, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P050019/S043
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- NIM
- Decision code
- APPR
- Decision date
- Sep 19, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent, carotid.
- Applicant
- Boston Scientific Corp
- Product code
- NIM
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P050019/S043 received
Application receipt date recorded by FDA.
P050019/S043 · FDA decision
Special (Immediate Track)
Timeline entries are records held by MedtechLedger for P050019. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code NIM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PROTEGE GPS AND PROTEGE RX CAROTID STENT SYSTEMSP060001/S060 | Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA |
| Contego Medical, Inc. | PMA supplement | Nov 4, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Contego Medical, Inc. | PMA supplement | Jul 29, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Jul 10, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- Three Scimed Pl., Maple Grove, MN, 55311
Sources and methodology
- Original FDA record: P050019/S043
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


